Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.82 |
| ▸ | JAK1 | P23458 | 2/20 | 0.82 |
| ▸ | JAK2 | O60674 | 1/20 | 0.82 |
| ▸ | TYK2 | P29597 | 1/20 | 0.82 |
| ▸ | PRKCH | P24723 | 19/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 19/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 19/20 | 0.69 |
| ▸ | PRKCA | P17252 | 18/20 | 0.69 |
| ▸ | PRKCB | P05771 | 17/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 16/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | PIM1 | P11309 | 2/20 | 0.69 |
| ▸ | MARK3 | P27448 | 2/20 | 0.69 |
| ▸ | LTK | P29376 | 2/20 | 0.69 |
| ▸ | GRK5 | P34947 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | GSK3A | P49840 | 2/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857150 | 0.85 | PRKCQ (0.72) | JAK3JAK1JAK2TYK2PRKCH | |
| SCHEMBL990717 | 0.84 | PRKCA (0.66) | JAK3JAK1JAK2TYK2PRKCH | |
| SCHEMBL6530244 | 0.82 | JAK1 (0.56) | JAK3JAK1JAK2TYK2PRKCH | |
| Sotrastaurin SCHEMBL29364923 | 0.82 | PRKCH (1.00) | JAK3JAK1PRKCHPRKCQPRKCD | |
| Sotrastaurin SCHEMBL2500835 | 0.82 | PRKCH (1.00) | JAK3JAK1PRKCHPRKCQPRKCD | |
| Sotrastaurin SCHEMBL29526075 | 0.82 | PRKCH (1.00) | JAK3JAK1PRKCHPRKCQPRKCD | |
| Sotrastaurin SCHEMBL3846239 | 0.79 | PRKCH (0.93) | JAK3JAK1PRKCHPRKCQPRKCD | |
| SCHEMBL4905416 | 0.79 | PRKCH (0.76) | JAK3JAK1PRKCHPRKCQPRKCD | |
| Sotrastaurin SCHEMBL29412439 | 0.79 | PRKCH (0.93) | JAK3JAK1PRKCHPRKCQPRKCD | |
| SCHEMBL21583796 | 0.79 | JAK3 (0.81) | JAK3JAK1JAK2TYK2PRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | claimed |
| US-7235555-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-06-26 | — | — | US | claimed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | claimed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | claimed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | NFATC1, CD4, LCK | JAK3 227/4885JAK1 130/4885JAK2 399/4885 |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | DGKK, DGKG, HLA-DRB1 | JAK3 181/4885JAK1 57/4885JAK2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.